Holen Sie sich die Stockscreener-App
79.96
0.26%
-0.21
Handel nachbörslich:
79.96
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt DXCM?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$80.17
Offen:
$80.67
24-Stunden-Volumen:
4.22M
Relative Volume:
1.23
Marktkapitalisierung:
$31.36B
Einnahmen:
$4.30B
Nettoeinkommen (Verlust:
$571.50M
KGV:
55.53
EPS:
1.44
Netto-Cashflow:
$570.80M
1W Leistung:
+4.66%
1M Leistung:
-4.09%
6M Leistung:
-4.91%
1J Leistung:
+12.59%
1-Tages-Spanne:
$79.87
$81.56
1-Wochen-Bereich:
$75.59
$81.56
52-Wochen-Spanne:
$57.52
$93.25
Dexcom Inc Stock (DXCM) Company Profile
Firmenname
Dexcom Inc
Sektor
Branche
Telefon
(858) 200-0200
Adresse
6340 SEQUENCE DRIVE, SAN DIEGO, CA
Vergleichen Sie DXCM mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
DXCM
Dexcom Inc
|
79.96 | 31.44B | 4.30B | 571.50M | 570.80M | 1.44 |
|
ABT
Abbott Laboratories
|
129.40 | 228.03B | 43.11B | 13.94B | 6.78B | 7.98 |
|
BSX
Boston Scientific Corp
|
102.50 | 152.09B | 18.49B | 2.50B | 3.49B | 1.68 |
|
SYK
Stryker Corp
|
378.95 | 143.98B | 23.82B | 2.92B | 4.02B | 7.55 |
|
MDT
Medtronic Plc
|
92.91 | 117.98B | 33.54B | 4.69B | 5.19B | 3.62 |
|
EW
Edwards Lifesciences Corp
|
77.68 | 45.17B | 5.69B | 1.41B | 577.90M | 6.95 |
Dexcom Inc Stock (DXCM) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-06-16 | Eingeleitet | Truist | Buy |
| 2025-05-30 | Eingeleitet | Goldman | Buy |
| 2025-04-10 | Eingeleitet | Mizuho | Outperform |
| 2025-02-03 | Hochstufung | Redburn Atlantic | Neutral → Buy |
| 2025-01-16 | Hochstufung | Robert W. Baird | Neutral → Outperform |
| 2024-07-26 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2024-07-26 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2024-05-30 | Eingeleitet | Redburn Atlantic | Neutral |
| 2024-03-12 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2023-05-30 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2023-04-17 | Hochstufung | Raymond James | Outperform → Strong Buy |
| 2023-03-29 | Eingeleitet | UBS | Buy |
| 2023-01-26 | Eingeleitet | Wolfe Research | Outperform |
| 2022-10-18 | Eingeleitet | Barclays | Equal Weight |
| 2022-10-12 | Eingeleitet | Jefferies | Buy |
| 2022-07-15 | Eingeleitet | Bernstein | Outperform |
| 2022-03-02 | Fortgesetzt | BofA Securities | Buy |
| 2022-02-03 | Hochstufung | BTIG Research | Neutral → Buy |
| 2022-01-19 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2022-01-07 | Hochstufung | Guggenheim | Neutral → Buy |
| 2021-10-18 | Herabstufung | Guggenheim | Buy → Neutral |
| 2021-07-21 | Fortgesetzt | Cowen | Outperform |
| 2021-05-28 | Hochstufung | Wells Fargo | Underweight → Equal Weight |
| 2021-05-25 | Eingeleitet | Barclays | Overweight |
| 2021-04-15 | Eingeleitet | Atlantic Equities | Overweight |
| 2021-01-06 | Hochstufung | UBS | Neutral → Buy |
| 2020-10-02 | Herabstufung | Wells Fargo | Equal Weight → Underweight |
| 2020-05-27 | Bestätigt | Piper Sandler | Overweight |
| 2020-05-14 | Eingeleitet | Wells Fargo | Equal Weight |
| 2020-03-05 | Eingeleitet | Citigroup | Buy |
| 2019-11-07 | Bestätigt | Canaccord Genuity | Buy |
| 2019-11-07 | Hochstufung | Guggenheim | Neutral → Buy |
| 2019-10-23 | Eingeleitet | Stifel | Buy |
| 2018-11-28 | Eingeleitet | UBS | Neutral |
| 2018-10-19 | Hochstufung | Goldman | Sell → Neutral |
| 2018-09-12 | Hochstufung | Northland Capital | Under Perform → Market Perform |
| 2018-08-02 | Bestätigt | Canaccord Genuity | Buy |
| 2018-07-02 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2018-06-08 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2018-05-11 | Eingeleitet | BofA/Merrill | Buy |
| 2018-05-03 | Bestätigt | Canaccord Genuity | Buy |
| 2018-04-04 | Eingeleitet | Goldman | Sell |
| 2018-04-04 | Eingeleitet | Guggenheim | Neutral |
| 2018-03-23 | Hochstufung | Robert W. Baird | Neutral → Outperform |
| 2018-01-04 | Herabstufung | Northland Capital | Market Perform → Under Perform |
| 2017-09-28 | Bestätigt | Wedbush | Outperform |
Alle ansehen
Dexcom Inc Aktie (DXCM) Neueste Nachrichten
FriskaAi Integrates with Dexcom’s CGM Data for AI-Powered Diabetes Management - HIT Consultant
FriskaAi and Dexcom Enter CGM Data Integration Agreement - The Joplin Globe
Saudi Arabia Blood Glucose Device Market Trends and Company Analysis Report 2025-2033 Featuring Abbott Laboratories, Medtronic, Dexcom, Braun, DarioHealth, Sanofi, Bionime, and Novo Nordisk - Yahoo Finance
5 Revealing Analyst Questions From DexCom’s Q2 Earnings Call - Yahoo Finance
DXCM Q2 CY2025 Deep Dive: Volume Growth, Leadership Changes, and New Product Launches Shape Outlook - ca.finance.yahoo.com
How much upside does DexCom Inc. haveFree Investment Webinars - thegnnews.com
Dexcom Shares Drop 1.28% on 0.33B in Volume Ranking 313th as Institutions Cut Holdings Despite Earnings Surge - AInvest
DexCom Inc. Recovery Likely Here’s What Data ShowsEntry Alert Based on Volume Spikes Detected - metal.it
Tandem, Insulet monitoring CMS payment proposal for diabetes tech - MedTech Dive
Dexcom and Apple Watch team up to 'empower Aussies living with diabetes' - iTWire
Insulet Peer Tandem Diabetes Underwhelming Earnings, Dull Outlook Drags Stock - Benzinga
Inside Dexcom’s strategy to stay ahead in the $13.6bn CGM market - Yahoo Finance
DEXCOM ALERT: Bragar Eagel & Squire, P.C. is Investigating - GlobeNewswire
Dexcom Rises 1.25% on Strong Earnings Amid Leadership Shift $370M Trading Volume Ranks 315th - AInvest
What You Need to Know Ahead of DexCom’s Earnings Release - MSN
Stock Analysis | Dexcom OutlookMixed Signals Amid Earnings and Tariff Uncertainty - AInvest
DexCom (DXCM) Extends Losses on Day 5 Amid Leadership Change - MSN
DexCom Extends Losses Amid Leadership Change Amid Q2 Revenue Growth - AInvest
Diabetes Management App Market Is Booming So Rapidly: Dexcom, Glooko, AgaMatrix - openPR.com
Dexcom, Inc. shares rise 1.22% premarket as equity markets rebound on Fed rate cut bets. - AInvest
Global Diabetes Management Software Market Outlook 2022 - openPR.com
Day 5 of Loss Streak for DexCom Stock with -15% Return (vs. -2% YTD) [8/4/2025] - Trefis
Dexcom recall triggered by reports of speaker malfunctions - BioWorld MedTech
DexCom, Inc. (DXCM) Stock Analysis: Impressive 28.76% Upside With Strong Buy Ratings - DirectorsTalk Interviews
What are analysts’ price targets for DexCom Inc. in the next 12 monthsCapitalize on stocks with high profit margins - Jammu Links News
How volatile is DexCom Inc. stock compared to the marketCapitalize on high-yield stock opportunities - Jammu Links News
Is it the right time to buy DexCom Inc. stockCapitalize on emerging market sectors - Jammu Links News
Is DexCom Inc. stock overvalued or undervaluedExceptional portfolio growth - Jammu Links News
What analysts say about DexCom Inc. stockTriple-digit returns - Jammu Links News
What institutional investors are buying DexCom Inc. stockOverwhelming financial success - Jammu Links News
Is It Time to Buy DexCom at a Discount Before Growth Fully Materializes? - AInvest
DexCom Inc. Stock Analysis and ForecastOverwhelming profit margins - Jammu Links News
How many analysts rate DexCom Inc. as a “Buy”Fastest-growing stock picks - Jammu Links News
How does DexCom Inc. generate profit in a changing economyMaximize your portfolio’s earning potential - Jammu Links News
DexCom raises 2025 revenue guidance to $4.625B as type 2 non-insulin access expands - MSN
Does DexCom Inc. stock perform well during market downturnsInvest smarter with real-time trading signals - Jammu Links News
DexCom Receives 'Buy' Rating from Canaccord Genuity; Analyst Raises Price Target to $106 - AInvest
What is the risk reward ratio of investing in DexCom Inc. stockInvest like a pro with expert recommendations - jammulinksnews.com
Investors Hope for Bounce in DexCom Inc. After SelloffValue Investing Picks With Stability Outlined - metal.it
Dexcom Reports Strong Q2 2025 Growth and Leadership Change - MSN
DexCom (DXCM) Receives 'Buy' Rating from Canaccord Genuity | DXC - GuruFocus
Commit To Purchase DexCom At $50, Earn 6.2% Using Options - Nasdaq
DexCom, Inc. (NASDAQ:DXCM) Q2 2025 Earnings Call Transcript - Insider Monkey
Raymond James Maintains Buy Rating for Dexcom with $102 Price Target - AInvest
DexCom (DXCM) Q2 Revenue Jumps 15% - The Globe and Mail
DexCom Inc. stock underperforms Thursday when compared to competitors - MarketWatch
Dexcom raises sales expectations, discusses G8 plans - MedTech Dive
DexCom stock price target raised to $106 from $105 at UBS - Investing.com Australia
DexCom (DXCM) Sees Target Price Upgrade Post-Quarterly Results - GuruFocus
Dexcom: Raymond James Keeps Strong Buy, PT Raised to $102 from $99. - AInvest
DexCom (DXCM) Receives a Price Target Boost from Baird - GuruFocus
Finanzdaten der Dexcom Inc-Aktie (DXCM)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.24%
0.31%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):